The diagnostics of the future

GenosmartDX is a bioinformatics and genomics platform that can be used in clinical diagnostic environments as well as for research purposes. It was designed to handle large-volume, parallel sequencing data. The system implements the processing of sequencing data, the automation of analysis workflows, and the clinical interpretation of results in a unified, scalable technological environment.

A urine-based, non-invasive prostate cancer risk assessment test based on the detection of the TMPRSS2–ERG gene fusion frequently associated with prostate tumors. Sampling is done from a simple urine sample without prostate massage, making the sampling gentle and possible to perform at home.

A blood plasma-based (ctDNA) liquid biopsy service developed for breast tumors, designed to track the molecular profile of the tumor over time. The test supports objective monitoring of therapeutic response and can help with the early identification of resistance mutations, often before clinical or radiological progression.

A blood plasma-based (ctDNA) liquid biopsy test related to lung tumors, focusing on the detection and follow-up of oncogenic alterations relevant to targeted treatments. It can help with the early identification of molecular changes and the emergence of resistance mutations alongside therapy, thereby supporting the timely fine-tuning of treatment strategy.

A 55-gene, NGS-based solid tumor panel test (from FFPE tumor tissue or plasma sample) for the identification of clinically relevant mutations, copy number alterations, and gene fusions. The structured report focuses on therapeutic decision support: it highlights alterations linked to targeted treatments, resistance mutations, and predictive markers associated with PARP inhibitors and immunotherapy.

BC-Alarm is a blood-based multimodal liquid biopsy developed for the detection of early-stage breast cancer, focusing on the investigation of platelet-bound RNA markers in addition to cfDNA. PC-Alarm Ultimate further develops urine-based prostate cancer risk assessment with a multimarker approach, as a supplement to PSA-based screening and to strengthen decision support.